Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $267.0052W HIGH $389.33
Volume
6.47 M
Value Traded
568.29 M
Short % Float
1.58%
Days to Cover
2.4
-4.98%Week
+5.98%1 Month
-10.39%3 Month
-0.97%6 Month
+23.84%5 Year
+379,668.4%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
111.95 B
EPS (TTM)
9.72
P/E Ratio
30.02
Ent. Value
122.85 B
Total Shares
383.53 M
Float Shares
361.01 M
Insiders
5.88%
Institutions
83.01%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SYK Catalyst Timeline
Dated clinical, regulatory and corporate events for Stryker Corporation
Catalyst Timeline
Dated clinical, regulatory & corporate events for Stryker Corporation
399Total events
6Upcoming
98Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲AcquiredCorporate
Stryker completes acquisition of ZuriMED, adding FiberLocker System to Sports Medicine portfolio
▲FDA ApprovalFDA Decision
FDA 510(k) clearance granted for Sonopet 3 ultrasonic tissue removal platform
ultrasonic bone and soft tissue removalsource ↗
▲Partnership / LicenseCorporate
Stryker and CMR Surgical announce strategic alliance for Versius portfolio
▲Equity OfferingCorporate
Stryker to make ~$400M (£300M) preferred equity investment in CMR Surgical
▼Legal / SettlementCorporate
Hagens Berman opens investigation into Stryker's disclosures regarding Inari Medical operations
▲Product LaunchProphecyPost-Market
Stryker launches Prophecy Surgical Planning for Incompass Total Ankle System
◆Oral PresentationPresentation
Stryker to participate in fireside chat at 2026 Wells Fargo Healthcare Conference
▼Safety Signal DisclosedSafety
CFO reveals Peripheral Vascular manufacturing issue persists into Q3 and expected into Q4 2026
peripheral vascularsource ↗
▲Product LaunchPost-Market
First surgical procedure using SportSuite Vision on Apple Vision Pro completed at Duke Health
hip arthroscopysource ↗
▼Supply DisruptionCMC / Inspection
Stryker discloses Peripheral Vascular supply disruptions and meaningful backorder in Q2 2026 results
peripheral vascularsource ↗
▲FDA ApprovalFDA Decision
FDA De Novo authorization for SportSuite Vision
intraoperative display of arthroscopic video and medical imaging during femoroacetabular impingement and labral repair hip arthroscopy proceduressource ↗
▲Product LaunchPost-Market
U.S. commercial launch of Mako RPS for total knee replacement
total knee replacementsource ↗
◆Timing GuidancePresentation
Management guidance that backorder should reach manageable level by end of Q3 2026
peripheral vascularsource ↗
◆Oral PresentationPresentation
Stryker presentation at Bank of America Securities 2026 Global Healthcare Conference
▲AcquiredCorporate
Stryker completes acquisition of Amplitude Vascular Systems
peripheral arterial diseasesource ↗
●Quarterly UpdateCorporate
Maintains FY2026 organic sales growth guidance 8.0%-9.5% and adjusted EPS $14.90-$15.10
◆AcquisitionCorporate
Stryker signs definitive agreement to acquire Amplitude Vascular Systems
calcified peripheral arterial diseasesource ↗
◆Oral PresentationPresentation
Stryker participation in 2025 Wells Fargo Securities Healthcare Conference Fireside Chat
◆Oral PresentationPresentation
Stryker presentation at Bank of America Securities 2025 Global Healthcare Conference
◆Management ChangeCorporate
Allan Golston to retire from Stryker Board of Directors at 2025 Annual Meeting
▲AcquisitionCorporate
Stryker completes sale of U.S. spinal implants business to Viscogliosi Brothers
◆Oral PresentationPresentation
Stryker presentation at Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Past FDA Catalysts and PDUFA Decisions
How SYK actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-06-05 | Spy Agent Green Kit (indocyanine green) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Pipeline Score
Pipeline Value
Valuation Signal
3
Drugs Scored
rNPV / MCap
Top Drug
Top 73%
Large Pharma(rank 480 of 657)
Percentile Rank
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Indocyanine Green Small moleculeMarketedNCT02070627 | Acute Cholecystitis | Phase 1 | COMPLETED | 6 | Aug 1, 2014 | ||||||
| Endovascular Treatment UnknownMarketedNCT02618031 | Acute Stroke | Phase 1 | COMPLETED | 57 | Dec 31, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every SYK program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Crotty Dylan BramOfficer (Group President) | Sell | -441 6,102 held | $328.61 | 08/21/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SYK
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.9 % (-25 %) | 50.09 M | 159.10 K | -12.82% ( -23.40 K) |
SYK Institutional Ownership Trends
SYK Short Interest
Shares sold short, counted twice a month.
1.58%
Short % of Float
of tradable shares sold short
5.7M
Shares Sold Short
-0.7% vs prior count
2.4 Moderate
Days to Cover
trading days of normal volume to buy every short share back
2.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SYK ranks across every disease it competes in
Competitive Position is a premium feature
See how SYK ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSYK News
SYK▼ -6.4%today
Stryker reports third quarter 2026 operating results
Stryker reported its third quarter 2026 results, showing a 7.7% increase in net sales to $6.5 billion. Adjusted earnings per share rose 10.3% to $3.52, despite a decrease in reported EPS by 11.7%. The company anticipates continued growth in Q4 and a solid performance heading into 2027.
Read more →SYK▼ -6.4%today
Stryker to participate in the 2026 Jefferies Global Healthcare Conference
Stryker will participate in the 2026 Jefferies Global Healthcare Conference on November 17, 2026. Key executives, including President Spencer Stiles and CFO Preston Wells, will take part in a fireside chat at 8:30 a.m. GMT. The session will be accessible via a live audio webcast.
Read more →SYKStryker completes acquisition of ZuriMED to enhance its shoulder offering
Stryker has completed its acquisition of ZuriMED, integrating the FiberLocker System into its Sports Medicine portfolio. This technology enhances rotator cuff repair by increasing biomechanical strength. The acquisition aims to support shoulder specialists with innovative treatment options and improve patient outcomes.
Read more →SYKStryker launches Sonopet® 3, delivering greater power and precision in ultrasonic tissue removal
Stryker has received FDA 510(k) clearance for its Sonopet 3, an advanced ultrasonic tissue removal platform. Designed with surgeon collaboration, it enhances power, precision, and workflow efficiency. Key features include RISE for integrated surgical experiences and Pulse Control for better tissue resection. Clinical use is expected to start in October 2026.
Read more →SYKStryker and CMR Surgical announce strategic alliance to advance robotic-assisted surgery
Stryker has entered a strategic alliance with CMR Surgical, investing approximately $400 million to enhance the Versius Surgical Robotic portfolio. This partnership allows Stryker to serve as the exclusive U.S. sales agent while CMR focuses on global commercialization. The collaboration aims to meet the growing demand for robotic-assisted surgeries and improve healthcare outcomes.
Read more →SYKStryker announces leadership succession
Stryker announced a leadership transition effective January 1, 2027, where Kevin Lobo will become Executive Chair, and Spencer Stiles will succeed him as CEO. Lobo has led the company for 14 years, significantly expanding its portfolio and global presence. Stiles, a long-time employee, is expected to continue this momentum and drive the company's growth.
Read more →SYKStryker (NYSE: SYK) Scrutinized Amid Disclosure of Persisting Peripheral Vascular Problems -- HBSS
Stryker Corporation's shares dropped sharply after the CFO disclosed that a previously resolved manufacturing issue in the Peripheral Vascular unit continues to affect supply. This revelation led to an investigation by Hagens Berman regarding the company's transparency about these ongoing problems. The situation has resulted in significant financial losses for investors and raised concerns about the company's operational integrity.
Read more →SYKStryker to announce third quarter 2026 financial results
Stryker will host a webcast on October 29, 2026, to discuss its third quarter financial results. The event will begin at 4:30 p.m. Eastern time, with a press release issued earlier at 4:05 p.m. The webcast will be accessible live and archived on Stryker's website.
Read more →SYKStryker showcases Foot & Ankle innovation at AOFAS 2026 with Prophecy® Surgical Planning for Incompass™ and Hoffmann® LRF smartHEX™
Stryker is showcasing new innovations at the AOFAS 2026 Annual Meeting, including the Prophecy Surgical Planning for the Incompass Total Ankle System and Hoffmann LRF smartHEX. These advancements aim to enhance surgical planning and implant flexibility, providing surgeons with improved tools for patient-specific care. The technologies reflect Stryker's commitment to integrating technology in orthopedic solutions.
Read more →SYK▼ -8.8%on this news
Schedule update: Stryker to participate in the 2026 Wells Fargo Healthcare Conference
Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on September 8, 2026. CFO Preston Wells and Investor Relations VP Nick Mead will engage in a fireside chat at 10:15 a.m. ET. The session will be available via live audio webcast, emphasizing Stryker's commitment to transparency and investor communication.
Read more →SYKStryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
Stryker has successfully completed the first surgical procedure using its FDA-authorized application, SportSuite Vision, on Apple Vision Pro at Duke Health. This innovative technology integrates critical clinical information into a surgeon's field of view, streamlining workflows during hip arthroscopy. The FDA's De Novo authorization signifies a major advancement in spatial computing for surgical applications.
Read more →SYKStryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
Stryker has signed a definitive agreement to acquire ZuriMED, known for its FiberLocker System, which enhances rotator cuff repair. This acquisition strengthens Stryker's shoulder portfolio and supports specialists in sports medicine and arthroplasty. The FiberLocker System aims to reduce clinical failure modes in rotator cuff repairs, a rapidly growing area in shoulder care. The transaction is subject to customary closing conditions.
Read more →SYKStryker to participate in the 2026 Wells Fargo Healthcare Conference
Stryker (NYSE:SYK) will participate in the 2026 Wells Fargo Healthcare Conference on September 8, 2026. CFO Preston Wells and Investor Relations VP Nick Mead will engage in a fireside chat at 2:15 p.m. ET. A live audio webcast will be available for those unable to attend in person.
Read more →SYKStryker spotlights the joint replacement journey and the vital role of caregivers at the 2026 BMW Championship
Stryker will showcase the caregiver experience in joint replacement at the 2026 BMW Championship. Honorary observers Tammy and Larry Accola-Newell will share their journey, emphasizing the caregiver's role in recovery. Attendees can learn about joint health, engage with orthopedic experts, and participate in activities at Stryker's Fan Activation.
Read more →SYKStryker declares an $0.88 per share quarterly dividend
Stryker Corporation has declared a quarterly dividend of $0.88 per share, payable on July 31, 2026, to shareholders recorded by June 30, 2026. This marks a 4.8% increase from the previous year, while remaining unchanged from the last quarter. Stryker is recognized for its innovative medical technologies.
Read more →SYK▼ -6.4%on this news
Stryker reports second quarter 2026 operating results
Stryker reported a strong second quarter for 2026, with net sales of $6.6 billion, reflecting a 9.4% increase. The company also saw a significant rise in earnings per share, which increased by 44.1% to $3.30. CEO Kevin A. Lobo highlighted the company's recovery from a cyber incident and expressed confidence in continued growth within the MedTech sector. The company has narrowed its full-year guidance, expecting organic net sales growth between 8.3% and 9.3%.
Read more →SYKStryker expands Mako robotics portfolio with full market release of Mako RPS
Stryker has launched the Mako RPS (Robotic Power System) for total knee replacement, expanding its Mako robotics portfolio. This new handheld technology integrates robotic execution with a familiar surgical experience, aiming to enhance accessibility for surgeons. The system is compatible with the clinically proven Triathlon Total Knee System and has received positive feedback during its limited release.
Read more →SYKStryker to announce second quarter 2026 financial results
Stryker will host a webcast on July 30, 2026, to discuss its second quarter financial results. The event will begin at 4:30 p.m. Eastern time, with a press release issued earlier at 4:05 p.m. This webcast will be accessible live and archived for later viewing on Stryker's website.
Read more →SYKStryker partners with professional golfer Shane Lowry to spotlight the caregiver journey in joint replacement
Stryker has partnered with golfer Shane Lowry to highlight the caregiver's role in joint replacement. Lowry, who has firsthand experience as a caregiver for his father, aims to raise awareness about the challenges faced by caregivers. The campaign will focus on education and support for those dealing with joint pain and recovery.
Read more →SYKStryker launches TPX HD® power tool, supporting demanding orthopaedic procedures
Stryker has launched the TPX HD power tool, aimed at enhancing performance in challenging orthopedic procedures. The tool is designed for total joint revisions and minimally invasive surgeries, featuring improved ergonomics and customizable control. Key attributes include increased torque and speed, making it a reliable choice for surgeons during demanding cases.
Read more →About Stryker Corporation
Headquarters1941 STRYKER WAY, PORTAGE, MI, 49002
BIOPHARMAWATCH ELITE PLUS
Trade the next SYK catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime